ERBB2 and neoplasm: Regarding the site of sampling (primary tumour versus metastases) larger heterogeneity is reported in different studies,22–25 ultimately confirming that specific clinico-pathologic features are not able to predict HER2 status when considered separately.10 In our series, tumour grading was the strongest predictor of HER2 status, in both cohorts.